CYXO — Cyxone AB Share News
0.000.00%
Last trade - 00:00- SEK14.25m
- SEK8.44m
Brief: Cyxone Q2 Loss Before Tax At SEK 12.7 Million
Brief: Cyxone Receives Pre-IND Response From FDA
Brief: Tara Heitner Steps Down As CEO Of Cyxone
Brief: Cyxone Q1 Loss Before Tax Widens To SEK 16.7 Million
Brief: Cyxone Q4 Pre-Tax Loss Widens To SEK 14.0 Mln
Brief: Cyxone Announces Outcome Of Rights Issue
Brief: Cyxone In Partnership With Contract Development & Manufacturing Organization
Brief: Cyxone Signs LOA With Clinical Contract Research Organization
Brief: Cyxone Executes Rights Issue Of SEK 66.9 Mln Secured To 91 Percent
Brief: Cyxone's Four Patent Applications Pertaining To Its Drug Candidate Rabeximod Published
Brief: Cyxone: Top-Line Results From Phase 2 Study Of Rabeximod In Covid-19 Patients
Brief: Cyxone Change Certified Adviser To FNCA
Brief: Cyxone Q3 Pre-Tax Loss Narrows To SEK 11 Mln
Brief: Cyxone Will Leverage Ind And Use FDA Pre-Review For Covid-19 Phase 2 Trial
Brief: Cyxone Q2 Loss Before Tax Narrows To SEK 11.5 Million
Brief: Cyxone Enters Collaboration With Medical University Of Vienna
Brief: Cyxone Explores Expanding Into New Regions To Mitigate Potential Delay In Covid-19 Trial Completion
Brief: Cyxone Appoints Henrik Hang As CFO
Brief: Cyxone Q1 Loss Before Tax Narrows To SEK 8.6 Mln